45/100 · Moderate
Manufactured by Kenvue Brands LLC
Minoxidil Adverse Events: Mild to Moderate Safety Concerns
65,386 FDA adverse event reports analyzed
Last updated: 2026-05-12
MINOXIDIL is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Kenvue Brands LLC. Based on analysis of 65,386 FDA adverse event reports, MINOXIDIL has a safety score of 45 out of 100. This moderate score indicates a notable volume of adverse event reports that patients and providers should be aware of. The most commonly reported adverse reactions for MINOXIDIL include ADVERSE DRUG REACTION, DRUG INEFFECTIVE, ALOPECIA, APPLICATION SITE PRURITUS, OFF LABEL USE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for MINOXIDIL.
Minoxidil has a safety concern score of 45 out of 100, placing it in the moderate concern category based on analysis of FDA adverse event data. The FDA has received approximately 65,386 adverse event reports for this medication, which is primarily manufactured by Kenvue Brands Llc.
The most commonly reported adverse events include Adverse Drug Reaction, Drug Ineffective, Alopecia. Of classified reports, 10.1% were designated as serious by the FDA, meaning they involved hospitalization, disability, or other significant medical outcomes. The majority of adverse events are non-serious, but application site issues and drug ineffectiveness are common.
Serious adverse events account for about 10% of reports, with cardiovascular and renal issues being notable. The safety profile is consistent across both male and female users, with no significant gender differences.
Patients taking Minoxidil should monitor for the commonly reported side effects and contact their healthcare provider if they experience any unusual symptoms. Minoxidil can cause cardiovascular and renal side effects, and should be used with caution in individuals with pre-existing conditions. It is contraindicated in patients with known hypersensitivity to the drug. This analysis is based on voluntary FDA adverse event reports and should not replace professional medical advice.
Minoxidil received a safety concern score of 45/100 (moderate concern). This is based on a 10.1% serious event ratio across 43,622 classified reports. The score accounts for 65,386 total adverse event reports and 100 distinct reaction types. This moderate score is typical for widely prescribed medications with established safety profiles.
Adverse event reports by sex: Male: 23,803, Female: 16,688, Unknown: 13. The most frequently reported age groups are age 69 (352 reports), age 70 (330 reports), age 65 (320 reports). These demographics reflect reporting patterns and may not represent the full patient population.
Out of 43,622 classified reports for MINOXIDIL:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
Minoxidil can cause cardiovascular and renal side effects, and should be used with caution in individuals with pre-existing conditions. It is contraindicated in patients with known hypersensitivity to the drug.
If you are taking Minoxidil, here are important things to know. The most commonly reported side effects include adverse drug reaction, drug ineffective, alopecia, application site pruritus, off label use. While many of these may be mild and temporary, you should contact your healthcare provider if any symptoms are severe or persistent. Follow the prescribed application instructions carefully to minimize the risk of skin irritation and other adverse events. Report any serious or unexpected side effects to your healthcare provider immediately. If you experience a serious adverse reaction, seek emergency medical attention immediately or call 911. You can report side effects to the FDA's MedWatch program at 1-800-FDA-1088.
The FDA continues to monitor minoxidil for safety, and updates are regularly issued. Healthcare providers should be vigilant for signs of serious adverse events and adjust dosing as necessary.
The FDA has received approximately 65,386 adverse event reports associated with Minoxidil. These reports come from healthcare professionals, consumers, and manufacturers through the FDA Adverse Event Reporting System (FAERS). Note that the number of reports does not directly indicate the frequency of side effects, as adverse events are voluntarily reported and may be underrepresented.
The most frequently reported adverse events for Minoxidil include Adverse Drug Reaction, Drug Ineffective, Alopecia, Application Site Pruritus, Off Label Use. By volume, the top reported reactions are: Adverse Drug Reaction (8,511 reports), Drug Ineffective (7,671 reports), Alopecia (3,741 reports). These figures reflect FDA adverse event reports and may not represent the true incidence rate of these side effects in all patients taking Minoxidil.
Out of 43,622 classified reports, 4,397 (10.1%) were classified as serious and 39,225 as non-serious. The FDA classifies an event as "serious" if it results in death, hospitalization, disability, or other medically significant outcomes. A higher serious-event ratio warrants closer attention but does not necessarily mean the drug is unsafe.
Adverse event reports for Minoxidil break down by patient sex as follows: Male: 23,803, Female: 16,688, Unknown: 13. This distribution reflects reporting patterns rather than actual risk differences between groups. Reporting rates can be influenced by prescribing patterns, disease demographics, and reporting behavior.
The most frequently reported age groups for Minoxidil adverse events are: age 69: 352 reports, age 70: 330 reports, age 65: 320 reports, age 67: 313 reports, age 71: 310 reports. Age-related reporting patterns can reflect both the demographics of the patient population and potential age-related susceptibility to certain side effects.
The primary manufacturer associated with Minoxidil adverse event reports is Kenvue Brands Llc. Multiple manufacturers may produce generic versions of this drug. The manufacturer listed reflects the most frequently reported brand in FDA adverse event data.
Beyond the most common reactions, other reported adverse events for Minoxidil include: Overdose, Application Site Irritation, Hair Texture Abnormal, Application Site Pain, Headache. Less common side effects can still be clinically significant. Patients should report any unusual symptoms to their healthcare provider.
You can report adverse events from Minoxidil to the FDA through their MedWatch program at www.fda.gov/medwatch, by calling 1-800-FDA-1088, or by completing Form FDA 3500. Healthcare professionals, consumers, and manufacturers can all submit reports. Reporting helps the FDA monitor drug safety after approval.
Minoxidil has a safety concern score of 45 out of 100 (moderate concern). This score is calculated from the ratio of serious to non-serious adverse events, the diversity of reported reactions, and the overall volume of reports relative to usage. The majority of adverse events are non-serious, but application site issues and drug ineffectiveness are common.
Key safety signals identified in Minoxidil's adverse event data include: Application site irritation and pruritus are the most frequently reported issues.. Drug ineffectiveness and off-label use are significant concerns, especially for hair growth.. Cardiovascular and renal issues, including hypertension and renal failure, are key safety signals.. These signals are derived from patterns in FDA reports and should be discussed with a healthcare provider for personalized assessment.
Minoxidil can cause cardiovascular and renal side effects, and should be used with caution in individuals with pre-existing conditions. It is contraindicated in patients with known hypersensitivity to the drug. Always inform your healthcare provider about all medications, supplements, and over-the-counter drugs you are taking before starting Minoxidil.
Follow the prescribed application instructions carefully to minimize the risk of skin irritation and other adverse events. Report any serious or unexpected side effects to your healthcare provider immediately.
Minoxidil has 65,386 adverse event reports on file with the FDA. Serious adverse events account for about 10% of reports, with cardiovascular and renal issues being notable. The volume of reports for Minoxidil reflects both the drug's usage level and the vigilance of the reporting community.
The FDA continues to monitor minoxidil for safety, and updates are regularly issued. Healthcare providers should be vigilant for signs of serious adverse events and adjust dosing as necessary. For the most current regulatory information, check the FDA's drug labeling database or consult your pharmacist.
Explore other medications manufactured by Kenvue Brands LLC and compare their safety profiles:
The following drugs share commonly reported adverse reactions with MINOXIDIL:
Drugs related to MINOXIDIL based on therapeutic use, drug class, or shared indications: